Exploring immune defects in young patients with blood disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the relationship between inborn errors of immunity and various hematologic disorders in patients under 25 years old. It aims to recruit individuals diagnosed with autoimmune cytopenias, polyclonal lymphoproliferation, malignant lymphoproliferation, or bone marrow failure/myelodysplasia. Participants will undergo extensive immunologic evaluations and genetic testing to identify both germline and somatic mutations. The goal is to better understand the immune defects associated with these conditions through a large prospective approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients age \< 25 years
2. Patients with diagnosed autoimmune cytopenias (AIC), polyclonal lymphoproliferation (PL), lymphoma (ML), bone marrow failure, and myelodysplastic syndrome (BMF/MDS) (see details below)
3. Signed Informed Consent

Exclusion Criteria:

1. Patients with Lymphoma secondary to HIV or transplant
2. Patient with self-resolving or post-infective AICs

Where it's running

• CHU Sainte-Justine
  Montreal, Canada, Canada Recruiting
• CHU Sainte-Justine
  Montreal, Canada, Canada Recruiting
• Institut Imagine
  Paris, France, France Recruiting
• Meyer Children's Hospital IRCCS, Firenze
  Florence, Fi, Italy Recruiting
• University of Rome Tor Vergata
  Rome, Italy, Italy Recruiting
• Vall d'Hebron Institut de Recerca
  Barcelona, Spain Recruiting

Study contacts

• Study coordinator: Eleonora Gambineri, MD
• Email: eleonora.gambineri@meyer.it
• Phone: +390555662624

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Romiplostim to help platelets grow after donor stem cell transplant

  This phase II trial tests whether weekly romiplostim helps patients over 18 who receive a haploidentical or fully matched unrelated donor stem cell transplant to engraft platelets faster than best supportive care.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07919977

• IL-5 CAR-T therapy for refractory or relapsed eosinophilic leukemia

  We will test whether IL-5 CAR-T cells can help adults with CD125-positive refractory or relapsed eosinophilic leukemia.

  Recruiting Phase 1 Zhejiang University · Hangzhou, Zhejiang · NCT07257640

• HLA mismatched stem cell transplantation for hematologic diseases

  This study is testing if using stem cells from donors who aren't a perfect match can help people with blood cancers get the treatment they need when they can't find a suitable donor.

  Recruiting Phase 1 Zhejiang University · Hangzhou, China · NCT06809699

• Go Wish Game to support advance care planning for adults with cancer or blood cancers

  This project tries the Go Wish Game to help adults with refractory leukemia, lymphoma, multiple myeloma, or advanced solid tumors and their caregivers have end-of-life conversations and complete advance care planning.

  Recruiting Azienda USL Reggio Emilia - IRCCS · Reggio Emilia · NCT06795815

• Home blood transfusions for people with advanced blood cancers in hospice

  The study will test whether offering home blood transfusions to adults with advanced or relapsed blood cancers who are eligible for hospice helps improve quality of life, mood, and end-of-life care.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06487247

• Assessing the effectiveness of teclistamab for multiple myeloma

  This study is testing if teclistamab can help people with relapsed or hard-to-treat multiple myeloma who have already tried at least three other treatments.

  Recruiting at 16 sites Universitaire Ziekenhuizen KU Leuven · Bonheiden, Antwerpen and 16 other locations · NCT06477783

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.